Gene therapy is described as a promising therapeutic approach for gastrointestinal diseases. The abstract names gene addition, gene editing, messenger RNA therapy, and gene silencing as strategy types.
First-pass extracted concept
gene therapy
Candidate: concept label6 source documents17 linked claims
Live refresh every 5sNext refresh in 5s
Extracted Explainers
What the tool is doing
Gene therapy is one of the major technology areas reviewed for Parkinson disease motor symptom management.
Gene therapy is presented as one of the future-oriented treatment strategies under investigation for Parkinson's disease.
Gene therapy is named as one therapeutic area in which nanoparticles can function as therapeutic agents.
Resources required
What problem it solves
It is positioned as an option when conventional pharmaceuticals and surgeries are not effective.
It is included as a promising treatment approach for PD motor symptoms.
It is discussed in the context of the need for disease-modifying treatments rather than symptom-only control.
The abstract places it within cancer therapy applications of nanoparticles.
What it does not solve
The abstract does not provide disease-specific efficacy, delivery details, or evidence that all gastrointestinal diseases are addressable by gene therapy.
The abstract does not specify which clinical or technical limitations remain unresolved.
The abstract does not support that gene therapy has definitively solved disease modification, noting mixed trial results.
Alternatives
The abstract explicitly contrasts gene therapy with conventional pharmaceuticals and surgeries.
The review places gene therapy alongside temporal interference, nanoparticles, BBB opening, optogenetics, and DREADDs.
The abstract groups gene therapy alongside immunotherapy and cell transplantation as disease-modifying strategies under study.
Evidence Snippets
Gene therapy is a promising approach for treating gastrointestinal diseases that are not effectively treated by conventional pharmaceuticals and surgeries. Gene therapy strategies include gene addition, gene editing, messenger RNA therapy, and gene silencing.
Furthermore, we explore emerging strategies, including gene therapy, stem cell therapy, cell type-specific neuromodulation, and AI-driven techniques for objective, unbiased pain assessment and research.
We highlight the following technologies: ... gene therapy...
Current technology iterations, such as gene therapy, stem cell therapy, and optogenetics, are advancing towards precise diagnosis and clinical applications.
To date, gene therapy, immunotherapy, and cell transplantation trials have had both promising and disappointing results.
This review article will discuss how nanoparticles are able to function as therapeutic agents in photodynamic, gene, and thermal therapy.
Supporting Sources
Linked Claims
Gene therapy strategies in this review include gene addition, gene editing, messenger RNA therapy, and gene silencing.
Gene therapy is a promising approach for gastrointestinal diseases that are not effectively treated by conventional pharmaceuticals and surgeries.
The review states that these innovative approaches are poised to enable discovery of safer and more effective analgesics.
Quoted textsource-backed
These innovative approaches are poised to revolutionize pain management, paving the way for the discovery of safer and more effective analgesics.
Opioid-dominated acute pain management is limited by addiction, tolerance, and dependence risks, motivating development of nonopioid analgesics.
Quoted textsource-backed
Acute pain management has historically been dominated by opioids, whose efficacy is overshadowed by the risks of addiction, tolerance, and dependence, culminating in the global opioid crisis. To transcend this issue, we must innovate beyond opioid-based μ receptor treatments, identifying nonopioid analgesics with high efficacy and minimal adverse effects.
Emerging nonopioid pain-management strategies discussed in the review include gene therapy, stem cell therapy, cell type-specific neuromodulation, and AI-driven techniques for objective unbiased pain assessment and research.
Quoted textsource-backed
Furthermore, we explore emerging strategies, including gene therapy, stem cell therapy, cell type-specific neuromodulation, and AI-driven techniques for objective, unbiased pain assessment and research.
Mechanism-based analgesic targets should be tailored to specific pain conditions including inflammatory, neuropathic, and nociplastic pain.
Quoted textsource-backed
This Review navigates the multifaceted landscape of inflammatory, neuropathic, and nociplastic pain, emphasizing mechanism-based analgesic targets tailored to specific pain conditions.
The reviewed studies establish the basis for novel and promising neuromodulatory treatments for Parkinson disease motor symptoms.
Quoted textsource-backed
These studies establish the basis for novel and promising neuromodulatory treatments for PD motor symptoms.
The review summarizes preclinical and clinical trials investigating innovative neuromodulatory approaches for Parkinson disease motor symptom management.
Quoted textsource-backed
In this review, we summarize preclinical and clinical trials investigating innovative neuromodulatory approaches for Parkinson disease (PD) motor symptom management.
The review highlights temporal interference, nanoparticles for drug delivery, blood-brain barrier opening, gene therapy, optogenetics, upconversion nanoparticles, magnetothermal nanoparticles, magnetoelectric nanoparticles, ultrasound-responsive nanoparticles, and DREADDs as relevant technologies for Parkinson disease.
Quoted textsource-backed
We highlight the following technologies: temporal interference, nanoparticles for drug delivery, blood-brain barrier opening, gene therapy, optogenetics, upconversion nanoparticles, magnetothermal nanoparticles, magnetoelectric nanoparticles, ultrasound-responsive nanoparticles, and designer receptors exclusively activated by designer drugs.
Molecular biology is the primary method for studying the genetic characteristics of RP and has been widely used in disease diagnosis and clinical trials.
Quoted textsource-backed
As the primary method for studying the genetic characteristics of RP, molecular biology has been widely used in disease diagnosis and clinical trials.
Retinitis pigmentosa is a genetically heterogeneous retinopathy caused by photoreceptor cell death and retinal pigment epithelial atrophy that eventually results in blindness.
Quoted textsource-backed
Retinitis pigmentosa (RP) is genetically heterogeneous retinopathy caused by photoreceptor cell death and retinal pigment epithelial atrophy that eventually results in blindness in bilateral eyes.
Gene therapy, stem cell therapy, and optogenetics are advancing toward precise diagnosis and clinical applications in RP.
Quoted textsource-backed
Current technology iterations, such as gene therapy, stem cell therapy, and optogenetics, are advancing towards precise diagnosis and clinical applications.
Multiple photoreceptor cell death types and pathological phenotypic changes in RP motivate deeper study of pathogenic mechanisms and may contribute to heterogeneous patient responses to mainstream drug treatment.
Quoted textsource-backed
Various photoreceptor cell death types and pathological phenotypic changes that have been disclosed in RP demand in-depth research of its pathogenic mechanism that may account for inter-patient heterogeneous responses to mainstream drug treatment.
Combining conventional therapy with state-of-the-art medication is presented as promising for transforming RP treatment strategies.
Quoted textsource-backed
The combination of conventional therapy and state-of-the-art medication is promising in revolutionizing RP treatment strategies.
There is a significant need for Parkinson's disease treatments that modify the disease process itself.
Quoted textsource-backed
there is a significant need for developing treatments to modify the disease process itself
Gene therapy, immunotherapy, and cell transplantation trials in Parkinson's disease have shown both promising and disappointing results.
Quoted textsource-backed
To date, gene therapy, immunotherapy, and cell transplantation trials have had both promising and disappointing results.
Nanoparticles are discussed as therapeutic agents in photodynamic therapy, gene therapy, and thermal therapy for cancer.
Quoted textsource-backed
how they can function as therapeutic agents in photodynamic, gene, and thermal therapy